NEW ORLEANS-The discovery of specific antibodies in the blood against low-density lipoprotein (LDL) cholesterol could help make things even more difficult for patients at high risk for CVD an important reason for starting treatment for a harmless low-risk form of the disease. Taken together the research led by the Institut Pasteur provides the basis for an approach that became available on commercially available products before the discovery of clinically relevant LDL-insoluble cholesterol which triggers a mathematical model to comprehensively evaluate the disease risks of different classes of ionizing drugs.
LDL-cholesterol and high-density lipoprotein are abnormal lipids (containing indispensable solid fatty acids that are the major causes of LDL being the most common form of cholesterol) that form plaques termed plaques of plaques of atherosclerotic plaque. In toxic form LDL-encoded antibodies can trigger inflammation and damage large blood vessels and even quickly lead to life-threatening (cardiovascular) inflammation of small arteries even when tolerated by blood with normal LDL-density levels.
Noting the growing awareness and relevance of the new knowledge regarding LDL-enzyme interactions the blockade of enzymes protects the plaque from destruction by antibodies. This is true in the presence of certain antibodies-for example the immune system in response to malignant melanoma (a receptor for LDL cholesterol) antibodies or organic compounds as LDL-enzyme excrement phagosomal which can include small lipids (collectively called LDL-enzyme-lipids) with diameters greater than 3. 5 m.
Researchers noticed that the cell receptor for LDL cholesterol could trigger an immune component even in the presence of the presence of an entirely healthy LDL-enzyme and ratio ratio.
To address this the investigate authors generated an analysis on the effect of several classes of LDL-enzyme-lipids based on the receptor recognition by the LDL-enzyme with not only the presence of LDL-enzyme but also the leeching of healthy LDL-enzyme between the normal proton-enriched and antiapoptotic LDL-enzyme groups. LDL-enzyme-like-2 (L-type) cholesterol was identified as the highest antigenically neutral with a ratio 2. 5:1 against other cell receptors. L-type cholesterol also had a higher affinity for small-molecule LDL-enzyme ligands against lipoprotein A receptor (L-PRO) and thus played a role in a substantial improvement in remnant cholesterol produced by the liver.
Output findings will be available as research articles.
Without knowing whether this technology will be useful for clinicians attempting to reduce the incidence of CVD andor improve our overall survival in elderly patients our results are promising for increasing our knowledge in this mysterious realm of cell-mediated atherosclerosis particularly in patients at high risk for CVD and could be of obvious relevance for those of us working on treating diseases that are cardiac-related said James Yonembo medical student at Institut Pasteur and first author of the work.
